GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX

January 27, 2013 | About:

GuruFocus

353 followers
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:



CVR Refining LP (CVRR): CEO and President John J. Lipinski Bought 200,000 Shares

CEO and President of CVR Refining LP (CVRR) John J Lipinski bought 200,000 shares on 01/17/2013 at an average price of $25 with a P/S ratio of 0.5095.

CFO and Treasurer Susan M. Ball bought 8,000 shares of CVRR stock on 01/17/2013 at the average price of $25. Susan M. Ball owns at least 8,000 shares after this. Other insiders have also increased their positions in the company.

Huntington Bancshares Inc (HBAN): President, CEO and Chairman Stephen D. Steinour Bought 40,000 Shares

President, CEO and Chairman of Huntington Bancshares Inc (HBAN) Stephen D. Steinour bought 40,000 shares on 01/23/2013 at an average price of $6.93. Huntington Bancshares Inc. was organized under Maryland law in 1966 and headquartered in Columbus, Ohio. Huntington Bancshares Inc has a market cap of $5.9 billion; its shares were traded at around $6.93 with a P/E ratio of 10.5 and P/S ratio of 2.2. The dividend yield of Huntington Bancshares Inc. stocks is 2.3%.

Huntington recently reported 2012 full-year net income of $641 million, an increase of $98.4 million, or 18%, from the prior year. 2012 fourth quarter net income of $167.3 million was essentially unchanged from the prior quarter. Earnings per common share for the year and current quarter were $0.71 and $0.19, respectively, up $0.12 and unchanged from the prior periods.

Ray Dalio owns 45,031 shares as of 09/30/2012, an increase of 135.38% from the previous quarter. This position accounts for 0.0042% of the $7.44 billion portfolio of Bridgewater Associates. Arnold Schneider owns 3,699,835 shares as of 09/30/2012, which accounts for 2.3% of the $1.09 billion portfolio of Schneider Capital Management.

CFO and Sr. Executive Vice President Donald R. Kimble bought 5,000 shares of HBAN stock on 08/15/2012 at the average price of 6.41. Donald R. Kimble owns at least 272,610 shares after this. The price of the stock has increased by 8.11% since. There are mixed trades from other insiders.

ValueVision Media Inc. (VVTV): CEO Keith R. Stewart Bought 100,000 Shares

CEO of ValueVision Media, Inc. (VVTV) Keith R Stewart bought 100,000 shares on 01/18/2013 at an average price of $2.61. ValueVision Media, Inc. was incorporated on June 25, 1990. Valuevision Media, Inc. has a market cap of $127.6 million; its shares were traded at around $2.61 with and P/S ratio of 0.2.

Executive Vice President and CFO William J. Mcgrath bought 10,000 shares of VVTV stock on 12/03/2012 at the average price of 1.79. William J. Mcgrath owns at least 106,680 shares after this. The price of the stock has increased by 45.81% since. Other insiders have also increased their positions in the company.

SunCoke Energy Partners LP (SXCP): Chairman and CEO Frederick A. Henderson Bought 12,000 Shares

Chairman and CEO of SunCoke Energy Partners LP (SXCP) Frederick A. Henderson bought 12,000 shares on 01/18/2013 at an average price of $0. with and P/S ratio of 0.8687.

SunCoke recently reported its fourth quarter preliminary results. Total U.S. coke production is expected to be nearly 1.1 million tons in fourth quarter 2012, up an estimated 67 thousand tons versus fourth quarter 2011. Full year 2012 U.S. coke production is expected to be more than 4.3 million tons, up an estimated 580 thousand tons versus 2011.

Senior Vice President and CFO Mark Newman bought 4,200 shares of SXCP stock on 01/18/2013 at the average price of 19. Mark Newman owns at least 4,200 shares after this.

Progenics Pharmaceuticals, Inc. (PGNX): CEO Mark Robert Baker Bought 1,215 Shares

CEO of Progenics Pharmaceuticals, Inc. (PGNX) Mark Robert Baker bought 1,215 shares on 01/22/2013 at an average price of $2.91. Progenics Pharmaceuticals Inc. or Progenics, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics Pharmaceuticals, Inc. has a market cap of $98 million; its shares were traded at around $2.91 with and P/S ratio of 13.2.

PGNX recently reported its third quarter 2012 financial results. Net loss for the third quarter of 2012 was $11.3 million or $0.33 basic and diluted per share, compared to net loss of $11.4 million or $0.34 per share in the 2011 period. Net loss for the nine months ended Sept. 30, 2012 was$35.1 million or $1.04 basic and diluted per share, compared to net income of $21.1 million or $0.63 per share in 2011.

For the complete list of stocks that bought by their company CEOs, go to: http://www.gurufocus.com/InsiderBuy.php?position=ceo

Rating: 4.0/5 (1 vote)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK